Novanta Inc.
NASDAQ•NOVT
CEO: Mr. Matthijs Glastra
セクター: Technology
業種: Hardware, Equipment & Parts
上場日: 1999-03-24
Novanta Inc., together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. The Precision Medicine and Manufacturing segment offers photonics-based solutions, including laser scanning, beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. The Robotics and Automation segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force and distributors under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, General Scanning, ATI Industrial Automation, Celera Motion, IMS, MicroE, Applimotion, Zettlex, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is headquartered in Bedford, Massachusetts.
連絡先情報
時価総額
$5.02B
PER (TTM)
99.9
29.6
配当利回り
--
52週高値
$149.95
52週安値
$98.27
52週レンジ
順位40Top 42.0%
4.1
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$258.35M+0.00%
直近4四半期の推移
EPS
$0.46+0.00%
直近4四半期の推移
フリーCF
$5.13M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Revenue Growth Strong Total revenue reached $980.6M, marking a 3.3% increase; Medical Solutions revenue grew 4.6% to $479.8M.
Major Equity Financing Closed Issued 6.50% tangible equity units, securing $613.1M net proceeds in November 2025 to bolster liquidity position.
Backlog Signals Future Demand Consolidated backlog increased to $481.2M as of year-end 2025, up from $445.5M in 2024, indicating order strength.
Automation Revenue Rises Automation Enabling Technologies segment revenue increased 2.1% to $500.8M, driven by robotics and automation product sales.
リスク要因
Operating Income Declined Operating income fell 15.0% to $94.0M in 2025, driven by higher SG&A and restructuring/acquisition related costs.
Customer Concentration Exposure Top two OEM customers represented 23% of 2025 consolidated revenue, posing concentration risk if orders significantly reduce.
Regulatory Complexity High Subject to extensive and dynamic medical device regulations across US, EU, and UK, increasing compliance complexity and costs.
Margin Pressure Evident Automation segment gross margin slightly decreased due to higher tariff costs and temporary increases from regional manufacturing strategy.
見通し
Medical Sales Mix Focus Strategy centers on improving business mix to increase medical sales percentage of total revenue via new product introductions.
Capital Structure Management Debt level stands at $259.6M total; $850.0M unused borrowing capacity available under the revolving credit facility.
Operational Efficiency Improvement Plans include strengthening operational performance via lean manufacturing and advancing strategic sourcing initiatives across major sites.
Technology Acquisition Strategy Will continue broadening portfolio through investment in new product development and pursuing complementary medical technology acquisitions.
同業比較
売上高 (TTM)
$5.30B
$4.13B
$3.71B
粗利益率 (最新四半期)
102.1%
65.5%
58.7%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| VICR | $9.15B | 77.5 | 18.7% | 1.6% |
| ESE | $7.27B | 23.9 | 21.3% | 7.9% |
| VNT | $5.88B | 14.4 | 34.0% | 48.9% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.4%
緩やかな成長
4四半期純利益CAGR
-6.3%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年5月4日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし